Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc > Wow
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(55)
•••
Post by Ingiboyon Feb 09, 2023 7:19pm
738 Views
Post# 35278500

Wow

WowThat is more like it !  Finally some volume:

Recent Trades - Last 10 of 13
Time ET Ex Price Change Volume Buyer Seller Markers
15:33:31 V 0.14 0.015 17,500 84 ITG84 79 CIBC K
15:33:31 V 0.14 0.015 10,000 84 ITG84 7 TD Sec K
15:33:31 V 0.14 0.015 22,000 84 ITG84 85 Scotia K
15:33:31 U 0.14 0.015 500 84 ITG84 2 RBC K
15:33:11 U 0.14 0.015 1,500 84 ITG84 2 RBC K
15:33:11 U 0.14 0.015 500 84 ITG84 2 RBC K
15:33:11 V 0.14 0.015 33,000 84 ITG84 85 Scotia K
13:55:35 V 0.125   15,000 84 ITG84 7 TD Sec K
09:30:00 V 0.13 0.005 450 2 RBC 80 National Bank  
09:30:00 V 0.13 0.005 150 2 RBC 80 National Bank
 
 
Nice to see some shares purchased on the open market.  ITG buying 100,000 shares.

Let's hope we see more action like this.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities